- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV)
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 1.1MB)
- Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 564.7KB)
Respiratory syncytial virus vaccine – November 2025
Respiratory syncytial virus vaccine: Solution for injection 50 µg in 0.5 mL pre-filled syringe; mResvia® - November 2025
Last updated
5 November 2025